ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Total Liabilities & Equity
ExpreS2ion Biotech Holding AB
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Total Liabilities & Equity
kr65.1m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Liabilities & Equity
kr1.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Liabilities & Equity
kr1B
|
CAGR 3-Years
41%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Liabilities & Equity
kr11.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
37%
|
CAGR 10-Years
27%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Liabilities & Equity
kr67.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Liabilities & Equity
kr2.6B
|
CAGR 3-Years
44%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Total Liabilities & Equity?
Total Liabilities & Equity
65.1m
SEK
Based on the financial report for Dec 31, 2025, ExpreS2ion Biotech Holding AB's Total Liabilities & Equity amounts to 65.1m SEK.
What is ExpreS2ion Biotech Holding AB's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-11%
Over the last year, the Total Liabilities & Equity growth was -38%. The average annual Total Liabilities & Equity growth rates for ExpreS2ion Biotech Holding AB have been -22% over the past three years , -11% over the past five years .
